Publications by authors named "S Mumusoglu"
Article Synopsis
- This study investigates whether daily subcutaneous administration of 25 mg progesterone improves the chances of live birth in women with low serum progesterone levels (7-10 ng/mL) before a frozen embryo transfer (FET).
- A cohort of 192 women was divided into three groups based on their progesterone levels and whether they received the rescue treatment, with the main focus on comparing live birth rates (LBR) among these groups.
- The results showed that the live birth rates were similar across the groups, indicating that adding the progesterone rescue treatment does not significantly improve outcomes for patients with low serum progesterone levels.
Importance: Preimplantation genetic testing for aneuploidy (PGT-A) to deselect aneuploid embryos in assisted reproductive technology (ART) treatment cycles may hold promise by augmenting pregnancy rates per transfer and reducing pregnancy loss rates for patients with unexplained recurrent pregnancy loss (RPL).
Objective: To explore effectiveness of PGT-A in managing unexplained RPL by evaluating several key aspects: the likelihood of live birth in a subsequent spontaneous pregnancy, whether women with unexplained RPL have a higher rate of aneuploidy, whether euploid blastocysts offer comparable live birth rate (LBR) in patients with unexplained RPL, whether the endometrium is less selective in unexplained RPL loss, and whether PGT-A increases the LBR or reduces pregnancy losses until delivery.
Data Sources: PubMed and Cochrane Library databases were searched from inception until June 2024.
Study Objective: The manner in which an individual experiences a polycystic ovary syndrome (PCOS) diagnosis may affect prognosis and vary with age. This study aimed to evaluate and compare the diagnosis experiences of adolescent and young adult PCOS patients.
Methods: PCOS patients from the same institution were divided into two groups according to age and clinic (adolescents diagnosed in the adolescent medicine clinic and young adults diagnosed in the obstetrics and gynecology clinic).
Objective: To assess the effect of dienogest treatment on endometrioma (OMA) size, serum anti-Mullerian hormone (AMH) levels and associated pain over a 12-month follow-up period.
Material And Methods: A longitudinal cohort study of 104 patients with OMA who were treated with dienogest, between January 2017 and January 2020. Of the included patients, each had a 12-month follow-up period with transvaginal or pelvic ultrasound and measurement of serum AMH concentration at the sixth and twelfth months of follow-up.